Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare Biotechnology

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > 2022 could be Latin America’s year..

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Mar 30, 2022 1:52pm

80 Views

Post# 34559780

RE:2022 could be Latin America’s year..

GoldenInvestor wrote: 2022 could be Latin America’s year as it fills the economic void left by Russia — How to play it

- opinions starting to warm to latin america.

I have not read the report, just could be interesting as sentiment begins to change regarding latam.

And the industry you are in is critical - some are much better than others.
Good to see our CFO is moving down to Head Office.
Good to see so big names join - lots of LATAM/Big Pharma experience.

I'm not afraid of LATAM - the key is how the business is developed - right people doing this.

Not an easy job for anyone ... if it were easy, it would already exist ... but no one has patience ... except for us !!!!!

<< Previous

Bullboard Posts

Next >>

3 Mid-Sized Stocks to Consider This Season